Ireland Establishes Clinical Trials Advisory Council to Transform National Clinical Research Landscape
核心洞察
Ireland's new Clinical Trials Advisory Council (搜索) (CTAC) held its inaugural meeting on 27 August 2026, marking a milestone in transforming the country's clinical trial landscape.
Chaired by Professor Donal Brennan (搜索), the Council brings together patient representatives, academia, healthcare providers, regulators, industry, and government to advance clinical research reforms.
CTAC will oversee implementation of the National Clinical Trials Oversight Group (搜索)'s Blueprint for Implementation, focusing on agile systems, workforce development, and innovative technologies.
The Minister for Health, Jennifer Carroll MacNeill TD, has welcomed the establishment and first meeting of the new Clinical Trials Advisory Council (搜索) (CTAC), marking another important milestone in transforming Ireland's clinical trial landscape. The inaugural meeting of the Clinical Trials Advisory Council took place on 27 August 2026.
The Clinical Trials Advisory Council (搜索) brings together a diverse range of expertise and perspectives from across Ireland's clinical research ecosystem, including patient representatives, healthcare providers, academia, industry, as well as Government Departments and agencies. The broad composition of the Council reflects the collaborative approach required to strengthen Ireland's clinical trials environment and deliver on the vision set out in the National Clinical Trials Oversight Group (搜索)'s (NCTOG's) final report.
Leadership and Mandate
The Council is chaired by Professor Donal Brennan (搜索), who was appointed by the Minister for Health. Donal Brennan is Professor of Gynaecological Oncology in University College Dublin (UCD) and Consultant Gynaecological Oncologist in the Mater Misericordiae University Hospital. He was previously the Chair of the National Clinical Trials Oversight Group (搜索) (NCTOG).
The establishment of the CTAC follows on from the successful work of the National Clinical Trials Oversight Group (搜索), whose final report, Transforming Ireland's Clinical Trials Landscape: A Blueprint for Implementation, was published by the Minister for Health in November 2025.
Strategic Priorities
The Council's role is to provide strategic advice and oversight on the implementation of the NCTOG recommendations, with a focus on several priority areas. These include the implementation and development of a National Clinical Trials Body, creating agile and responsive systems, enhancing public and patient engagement, promoting value and incentivising activity, supporting strategic workforce development, and promoting the use of innovative technologies in clinical trials.
The Council also supports alignment between the clinical trials agenda and broader national and international policy objectives. By bringing together representatives from across the clinical trials ecosystem, the Council supports collaboration to accelerate the development of innovative treatments from research to real-world use, enhance public and patient engagement, and ensure earlier access to clinical trials and emerging therapies.
Significance for Patients and the Research Ecosystem
Clinical trials play a vital role in improving health outcomes for patients and their families by providing access to innovative treatments and preventative interventions. They also contribute to Ireland's economic and research ecosystem by supporting high-value employment, fostering innovation and strengthening Ireland's competitiveness as a location for clinical research.
The establishment of the Council reflects the Government's commitment to transforming Ireland's clinical trials landscape through a more coordinated, efficient and patient-centred approach. The Council's membership reflects the breadth of stakeholders involved in the delivery of clinical trials in Ireland, including patient representatives, academia, healthcare providers, regulators, industry, and Government Departments and agencies, ensuring a collaborative and inclusive approach to advancing Ireland's clinical trials ambition.